and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same price as NovoLog (insuin aspart), while Tresiba's price will be reduced ...
Very low blood sugar may result. Do not change brands or types of insulin without directions on how to do so from your doctor. Do not share your pen device with another person, even if the needle ...
The list prices of its insulin drug Fiasp will be reduced by 75%, while the list prices of its Tresiba insulin will be reduced by 72.2%, Novo said in a statement. As a result, Novo will discontinue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results